Healthy Mind - Testing if an Online Tool Can Help People with Borderline to-Mild Intellectual Disability Improve Their Mental Health

Not Applicable

Recruiting

• Conditions: Intellectual Disability; Depression; Anxiety; Mental Health - Other mental health disorders; Mental Health - Depression; Mental Health - Anxiety

• Registration Number: ACTRN12620000113954
• Lead Sponsor: Dr Peter Baldwin

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-02-07
• Last Update Posted: 5 July 2021

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 150

Inclusion Criteria

Are an Australian resident aged 16 years or over.
-Have a previous diagnosis of a borderline-to-mild ID (diagnosis of borderline-to-mild ID will be confirmed by the nominated carer, and an estimate of cognitive functioning will be obtained prior to commencement of the trial using Cambridge Brain Science online assessment platform.
-Report mild-to-moderate symptoms of depression and/or anxiety.
-Can nominate a study helper” to assist them throughout trial participation (Each study participant will nominate a trusted carer to provide support throughout all trial stages. A study helper may be a carer, support-worker, family member, friend or other trusted individual. Consent, screening and all other data collection will be completed online with study helper support).

Exclusion Criteria

-Report ID severity greater than mild.
-Report severe mental health problems (severe symptoms of anxiety and/or depression, severe mood disturbance and/or mania, suicidal ideation, psychotic symptoms).
-Are experiencing medical comorbidities or other functional impairments that might impede trial engagement (e.g. impaired vision, hearing, motor skills etc.).
-Are not an Australian resident.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Anxiety Depression and Mood Scale (ADAMS)[Immediate prior to treatment; immediately after completing the treatment phase (i.e. 8 weeks after Time 1); and again 3-months after completing treatment (i.e. 3-month after Time 2).]

Secondary Outcome Measures

Name	Time	Method
Kessler 10[Immediate prior to treatment; immediately after completing the treatment phase (i.e. 8 weeks after Time 1); and again 3-months after completing treatment (i.e. 3-month after Time 2).];WHO-DAS 2[Immediate prior to treatment; immediately after completing the treatment phase (i.e. 8 weeks after Time 1); and again 3-months after completing treatment (i.e. 3-month after Time 2).]